Treatment of HIV and HBV coinfection

In The Lancet HIV, Anchalee Avihingsanon and colleagues 1 Avihingsanon A Lu H Leong CL et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. Lancet HIV. 2023; (published online July 24.)https://doi.org/10.1016/S2352-3018(23)00151-0 PubMed Google Scholar report the results of a double-blind, randomised controlled non-inferiority trial comparing bictegravir, emtricitabine, and tenofovir alafenamide and dolutegravir, emtricitabine, and tenofovir disoproxil fumarate regimens in people with HIV and HBV coinfection who were naive to antiretroviral therapy. The coprimary endpoints were the proportion of patients with HIV-1 and HBV viral suppression (HIV-1 RNA <50 copies per mL and HBV DNA <29 IU/mL) at week 48, which were also assessed at week 96 as additional endpoints. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trialCoformulated bictegravir, emtricitabine, and tenofovir alafenamide is an effective therapy for adults with HIV-1 and HBV coinfection starting antiviral therapy. Full-Text PDF